Good morning, everyone. Damian Garde here, filling in for Ed Silverman in the waning hours of another working week. Just beyond today’s meetings, deadlines, and reply-all emails awaits the weekend. Perhaps you’ve planned an escape from wherever it is you’ve been holed up, a lengthy walk outdoors, or just some time nearer to thine couch. Be safe, whatever you do. And in the meantime, here are your requisite tidbits to begin this Friday. Do, as always, stay in touch.

President Trump promised a vaccine for Covid-19 “before the end of the year, or maybe even sooner” during a speech at the Republican National Convention on Thursday, STAT tells us. That pledge marks the most definitive timetable Trump has put on the normally lengthy process of developing a vaccine. And his declaration is certain to fuel anxiety that the White House will pressure the Food and Drug Administration to approve a vaccine candidate before data from large-scale clinical trials are available.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy